dc.contributor | Matijasevic, Eugenio | |
dc.contributor | Pedraza Flechas, Ana María | |
dc.creator | Hoyos Velasco, Alba | |
dc.creator | Hernández Ospina, Michael Stanley | |
dc.date.accessioned | 2021-07-23T21:29:11Z | |
dc.date.accessioned | 2022-09-22T14:09:16Z | |
dc.date.available | 2021-07-23T21:29:11Z | |
dc.date.available | 2022-09-22T14:09:16Z | |
dc.date.created | 2021-07-23T21:29:11Z | |
dc.identifier | https://repository.urosario.edu.co/handle/10336/31902 | |
dc.identifier | https://doi.org/10.48713/10336_31902 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3436263 | |
dc.description.abstract | Introduction: Clostridium difficile constitutes one of the main pathologies associated with hospital care in developed countries, in Colombia there are few studies, an affected population was characterized. Methodology: Retrospective descriptive study, which describes the clinical characteristics of patients who presented this pathology in the IV level hospital in Bogotá from 2015 to 2019. Results. 243 cases were collected, 198 of the first time and 45 recurrences, the mean age was 62.4 years, 66.2% corresponded to the female gender. In 72.5% the symptoms were less than 10 days, mainly abdominal pain and diarrhea, 86.4% took a previous antibiotic, the suspension time and the appearance of symptoms was less than 7 days in 75.7% of the cases. 35% consumed ampicillin sulbactam, 25% piperacillin tazobactam, meropenem 15%, ertapenem 8.5%, linezolid 5.26% and 3.29% amoxicillin clavulanic acid. 85.8% had enteral nutrition, 11% mixed and 3.2% parenteral, 94% consumed proton pump inhibitors. Diabetes mellitus, kidney and heart failure, and immunosuppression were the main risk factors. The main diagnostic method was the polymerase chain reaction. 96% received antimicrobial treatment vancomycin and metronidazole. Hospitalization in 42.6% was longer than 21 days. 83% did not require admission to the ICU, there were 7 deaths in the 5 years. Conclution: Consumption of antibiotics widely related to this pathology, one must be cautious when formulating them, to avoid putting patients at risk, increasing hospital stay and the use of health resources. | |
dc.language | spa | |
dc.publisher | Universidad del Rosario | |
dc.publisher | Especialización en Medicina Crítica y Cuidado Intensivo | |
dc.publisher | Escuela de Medicina y Ciencias de la Salud | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Abierto (Texto Completo) | |
dc.rights | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.
PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.
EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.
--------------------------------------
POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | |
dc.rights | Atribución-NoComercial-SinDerivadas 2.5 Colombia | |
dc.source | 1.Chan H, Zhao S, Zhang L, Ho J, Leung CCH, Wong WT, et al. Clostridium difficile toxin B induces autophagic cell death in colonocytes. Journal of cellular and molecular medicine. 2018;22(4):2469-77 | |
dc.source | 2.Riley TV, Kimura T. The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review. Infectious diseases and therapy. 2018;7(1):39-70. | |
dc.source | 3.Alcalá-Hernández L, Mena-Ribas A, Niubó-Bosh J, Marín-Arriaza M. Diagnóstico microbiológico de la infección por Clostridium difficile. Enfermedades Infecciosas y Microbiología Clínica. 2016;34(9):595-602. | |
dc.source | 4.Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis. Anaerobe. 2018;50:32-7. | |
dc.source | 5.Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375-90 | |
dc.source | 6.Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147-54 | |
dc.source | 7.Aitken S, Shah D, Garey K. Economic burden of Clostridium difficile infection. 2013. p. 60-80. | |
dc.source | 8.World Health O. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). Geneva: World Health Organization; 2003. | |
dc.source | 9.Carvalho AV, Medeiros-Júnior AC de, Chaves BMF, Xavier CRS, Rêgo ACM do, Araújo-Filho I, et al. Pseudomembranous Colitis – a review. J Surg Clin Res.2014;4(2):63. | |
dc.source | 10.Fitzpatrick F, Skally M, Brady M, Burns K, Rooney C, Wilcox MH. European Practice for CDI Treatment. Adv Exp Med Biol. 2018;1050:117-35. | |
dc.source | 11.Rock C, Pana Z, Leekha S, Trexler P, Andonian J, Gadala A, et al. National Healthcare Safety Network laboratory-identified Clostridium difficile event reporting: A need for diagnostic stewardship. Am J Infect Control. 2018;46(4):456-8. | |
dc.source | 12.Asensio Á, Bouza E, Grau S, Rubio-Rodríguez D, Rubio-Terrés C. Coste de la diarrea asociada a Clostridium difficile en España. Revista Española de Salud Pública. 2013;87:25-33. | |
dc.source | 13.Sierra-Hernández A, Estrada-Hernández LO. Antibiótico más relacionado con colitis por antimicrobianos en pacientes hospitalizados. Med Interna Mex. 2016;32(3):330–40 | |
dc.source | 14.Davis BM, Yin J, Blomberg D, Fung IC. Impact of a prevention bundle on Clostridium difficile infection rates in a hospital in the Southeastern United States. Am J Infect Control. 2016;44(12):1729-31. | |
dc.source | 15.Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4(4):409-16. | |
dc.source | 16.Khanna R, Chande N, Nelson RL. Treatment of an Initial Infection with Clostridium difficile in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2013;19(10):2223-6. | |
dc.source | 17.Rodriguez-Pardo D, Mirelis B, Navarro F. Infections caused by Clostridium difficile. Enferm Infecc Microbiol Clin. 2013;31:254–63. | |
dc.source | 18.Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23(3):529–49. | |
dc.source | 19.Oñate-Gutiérrez JM, et al. Prevalencia y factores relacionados con la infecciónpor Clostridium difficile en un centro hospitalario de alta complejidad en Cali (Colombia). Infectio. 2016;(18) 9-14 | |
dc.source | 20.Blanco Pérez Ángela, Ruiz Morales Óscar, Otero Regino William, Gómez Zuleta Martín. Infección por Clostridium difficile en ancianos. Rev Col Gastroenterol; 28(1):53-63 | |
dc.source | 21.Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Suppl 2:1-26. | |
dc.source | 22.Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. Bmj. 2010;34 | |
dc.source | 23.Owens RC, Jr., Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S19-31. | |
dc.source | 24.Karen C. C, John G. B. Biology of Clostridium difficile : Implications for Epidemiology and Diagnosis. Annu Rev Microbiol. 2011;65(1):501–21. | |
dc.source | 25.McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. | |
dc.source | 26.Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98. | |
dc.source | 27.Debast SB, Bauer MP, Kuijper EJ, Allerberger F, Bouza E, Coia JE, et al. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(S2):1–26 | |
dc.source | 28.Williams OM, Spencer RC. The management of clostridium difficile infection. Br Med Bull. 2009;91(1):87–110. | |
dc.source | 29.Arteaga A, Santa-Olalla P, Sierra MJ, Limia A, Cortés M, Amela C. [Epidemic risk of disease associated with a new strain of Clostridium difficile]. Enferm Infecc Microbiol Clin. 2009;27(5):278-84. | |
dc.source | 30.Esteban-Vasallo MD, Naval Pellicer S, Domínguez-Berjón MF, Cantero Caballero M, Asensio Á, Saravia G, et al. Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period. Eur J Clin Microbiol Infect Dis. 2016;35(6):1037-44. | |
dc.source | 31.Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211-21. | |
dc.source | 32.He K, Hu Y, Shi JC, Zhu YQ, Mao XM. Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China. Ther Clin Risk Manag. 2018;14:403-8. | |
dc.source | 33.Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, et al. Risk Factors Associated with Recurrent Clostridioides difficile Infection. Healthcare (Basel, Switzerland). 2020;8(3):352. | |
dc.source | 34.Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326-32 | |
dc.source | 35.Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond). 2018;18(3):237-41. | |
dc.source | 36.O'Keefe SJ. Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol. 2010;16(2):139-42. | |
dc.source | 37.Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold WL, Muller MP, et al. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. Clin Infect Dis. 2015;61(12):1781-8. | |
dc.source | 38.Kukla M, Adrych K, Dobrowolska A, Mach T, Reguła J, Rydzewska G. Guidelines for Clostridium difficile infection in adults. Przeglad gastroenterologiczny. 2020;15(1):1-21. | |
dc.source | instname:Universidad del Rosario | |
dc.source | reponame:Repositorio Institucional EdocUR | |
dc.subject | Caracterización clínica de la infecciones por bacteria Clostridium difficile | |
dc.subject | Correlación consumo de antibióticos con infecciones por Clostridium difficile en Colombia | |
dc.subject | Manejo antimicrobiano con vancomicina y metronidazol en el tratamiento por Clostridium difficile | |
dc.title | Características clínicas de pacientes con infección por Clostridium difficile en un hospital de IV nivel Bogotá 2015-2019 | |
dc.type | masterThesis | |